parapsoriasis: one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying etiology. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
114 |
4. Check minimum number of eventsNone |
114 |
5. Include endpointsNone |
114 |
6. Filter based on genotype QC (FinnGen only) |
99 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Small plaque parapsoriasis
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 705 | 263 | 436 |
| Only index persons | 632 | 248 | 384 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.16 | 63.44 | 64.43 |
| Only index persons | 63.20 | 62.86 | 63.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 99 | 40 | 59 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.03 |
| Median age at first event (years) | 63.30 | 63.57 | 63.13 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 102
- Matched controls
- 1020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L41.3
ICD-10 Finland
Small plaque parapsoriasis
+∞
74.3
62
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
31.4
72.5
65
54
L41.4
ICD-10 Finland
Large plaque parapsoriasis
+∞
45.2
40
*
D07AC01
ATC
betamethasone; topical
10.4
29.0
76
224
L41.9
ICD-10 Finland
Parapsoriasis, unspecified
+∞
26.2
24
*
E0000UV, ,
ATC
9.5
24.3
80
283
D07AB02
ATC
hydrocortisone butyrate; topical
7.0
21.9
63
191
D07AB08
ATC
desonide; topical
8.2
21.0
35
61
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
+∞
18.3
17
*
E000001, ,
ATC
6.0
17.3
43
110
L30.9
ICD-10 Finland
Dermatitis, unspecified
5.8
16.7
43
113
D07AC13
ATC
mometasone; topical
5.5
16.7
56
185
E000002, ,
ATC
7.5
16.4
28
49
L40.0
ICD-10 Finland
Psoriasis vulgaris
101.0
16.1
17
*
L41.8
ICD-10 Finland
Other parapsoriasis
+∞
16.0
15
*
D07AD01
ATC
clobetasol; topical
5.8
15.2
36
87
D07AA02
ATC
hydrocortisone; topical
5.4
13.2
33
83
L41.1
ICD-10 Finland
Pityriasis lichenoides chronica
+∞
12.8
12
*
C84.0
ICD-10 Finland
Mycosis fungoides
134.6
11.7
12
*
D05BB02
ATC
acitretin; oral
61.0
9.9
11
*
D05AX02
ATC
calcipotriol; topical
30.5
8.7
11
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.9
8.2
20
48
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.5
8.0
38
148
ZXC50
NOMESCO Finland
Cryotherapy
10.6
7.6
14
15
L40.9
ICD-10 Finland
Psoriasis, unspecified
+∞
7.4
7
*
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
15.2
7.1
11
8
XQ848
NOMESCO Finland
Dermatological photography
9.7
6.8
13
15
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
6
5
12.62
3.81
1.7
2.8
0.33
0.60
index
—
6
5
9
20
4.83
3.19
1.6
1.6
—
—
—
0
0
22
111
2.25
2.60
1.7
2.0
—
—
—
0
0
8
22
3.85
2.42
2.9
2.3
425.00
308.87
ug/l
—
8
22
7
17
4.34
2.40
1.0
1.4
—
—
—
0
0
22
115
2.16
2.39
1.7
1.8
—
—
—
0
0
7
18
4.09
2.29
1.4
1.4
—
—
—
0
0
7
18
4.09
2.29
1.7
1.4
—
—
—
0
0
7
18
4.09
2.29
1.4
1.4
—
—
—
0
0
5
9
5.77
2.24
1.6
1.2
—
—
—
0
0
7
21
3.50
2.00
1.0
1.2
—
—
—
0
0
61
472
1.73
1.91
4.2
4.3
0.00
15.77
estimate
0.50
13
103
61
476
1.70
1.82
4.3
4.3
0.00
0.00
estimate
-0.00
13
89
6
18
3.47
1.77
1.0
1.4
—
—
—
0
0
7
24
3.05
1.75
1.7
1.2
—
—
—
0
0
60
469
1.68
1.75
4.2
4.2
0.00
0.00
estimate
-0.00
13
99
22
129
1.90
1.74
1.3
1.4
0.96
13.66
u/ml
—
5
50
5
13
3.99
1.73
7.8
2.8
—
—
—
0
0
29
189
1.75
1.64
2.0
1.7
0.70
1.14
mg/l
1.41
22
156
7
26
2.81
1.61
1.4
1.4
—
—
—
0
0
94
855
2.27
1.53
31.8
23.7
77.20
82.10
umol/l
1.53
94
846
42
310
1.60
1.48
2.2
3.7
1365.44
1335.46
ng/l
0.02
32
263
22
137
1.77
1.44
2.9
3.2
0.67
2.53
e6/l
1.25
11
66
9
40
2.37
1.44
2.3
2.5
—
—
—
0
0
9
40
2.37
1.44
1.9
2.1
3.04
3.23
g/l
—
9
35
20
121
1.81
1.44
2.8
7.0
2.19
1.03
mmol/l
0.59
13
102
17
98
1.88
1.41
3.1
3.9
—
—
—
0
0
9
41
2.31
1.41
1.9
2.1
13.29
9.61
g/l
—
9
35
45
342
1.57
1.38
2.2
2.0
1.44
1.30
mmol/l
0.43
39
282
23
148
1.72
1.35
1.7
2.0
—
—
—
0
0
9
44
2.14
1.30
1.9
2.0
4.79
3.83
g/l
—
9
39
9
44
2.14
1.30
1.9
2.0
4.34
4.50
g/l
—
9
39
9
44
2.14
1.30
1.9
2.0
7.36
7.66
g/l
—
9
39
8
36
2.32
1.27
2.0
2.3
0.00
0.00
g/l
—
8
30
87
782
1.77
1.21
5.6
5.4
4.50
4.48
mmol/l
0.06
79
724
0
33
0.00
1.18
0.0
1.5
—
—
—
0
0
8
39
2.14
1.18
2.0
2.2
0.00
0.47
g/l
—
8
34
28
197
1.58
1.17
3.5
4.8
1.01
1.02
kg/l
1.26
16
137
87
784
1.75
1.17
23.3
18.2
79.68
77.59
ml/min/173m2
0.45
82
738
22
147
1.63
1.13
1.6
1.7
1176.72
1335.73
nmol/l
0.40
17
114
14
82
1.82
1.12
2.6
2.1
1.84
1.55
%
0.38
14
71
10
52
2.02
1.10
1.0
1.9
—
—
—
0
0
9
45
2.09
1.08
1.4
1.4
—
—
—
0
0
82
733
1.61
1.07
5.9
5.2
1.91
2.03
mu/l
0.30
76
665
22
149
1.61
1.07
2.9
3.0
0.44
0.81
e6/l
0.76
11
77
86
780
1.65
1.03
5.5
5.3
1.37
1.42
mmol/l
0.54
76
719
11
61
1.90
1.03
1.2
1.3
—
—
—
0
0
57
476
1.45
1.03
7.2
7.0
12.86
11.81
umol/l
0.43
57
450
85
769
1.63
1.02
5.6
5.4
5.91
6.08
mmol/l
0.65
77
705
37
289
1.44
0.93
4.5
4.9
25.06
21.12
%
0.77
14
138
8
44
1.89
0.88
4.1
3.4
4.79
4.37
pmol/l
—
8
36
69
607
1.42
0.87
4.8
4.2
15.34
15.00
pmol/l
0.56
63
550
87
801
1.59
0.85
6.9
6.2
2.76
2.58
mmol/l
1.00
79
740
35
276
1.41
0.83
2.8
3.0
35.40
31.26
u/l
0.44
35
259
8
47
1.76
0.83
1.0
1.8
—
—
—
0
0
46
381
1.38
0.82
3.2
2.8
—
—
estimate
—
0
0
6
33
1.87
0.80
1.0
1.3
—
—
—
0
0
20
143
1.50
0.78
3.1
6.7
101.30
103.34
mmol/l
0.82
20
143
5
25
2.05
0.74
1.6
1.5
1.13
1.20
g/l
—
5
25
5
25
2.05
0.74
1.6
1.4
0.21
0.23
g/l
—
5
25
11
69
1.67
0.71
1.4
1.5
—
—
—
0
0
5
26
1.97
0.71
3.4
1.3
—
—
—
0
0
7
41
1.76
0.71
2.3
3.1
110.00
930.08
u/ml
—
7
36
45
378
1.34
0.71
3.1
2.1
96.37
97.07
pmol/l
0.04
28
198
34
274
1.36
0.70
2.0
1.8
20.98
22.05
nmol/l
0.15
28
219
5
27
1.89
0.69
2.4
2.2
207.20
219.04
%
—
5
27
24
183
1.41
0.68
1.5
1.3
1.08
1.08
u/ml
—
5
57
13
88
1.55
0.64
4.2
2.7
69.81
66.31
g/l
0.87
13
79
0
20
0.00
0.61
0.0
2.0
—
—
—
0
0
0
22
0.00
0.60
0.0
2.1
—
—
—
0
0
30
243
1.33
0.59
4.6
3.3
359.42
356.85
umol/l
0.05
24
210
8
54
1.52
0.59
1.1
3.6
1.14
1.12
%
—
8
54
86
808
1.41
0.56
25.8
17.8
27.83
24.98
mg/l
0.32
75
683
31
255
1.31
0.55
3.5
3.6
0.00
0.00
estimate
-0.00
12
74
41
351
1.28
0.54
3.9
4.4
0.00
0.04
estimate
0.49
12
77
33
277
1.28
0.50
3.2
3.0
0.31
0.31
e6/l
0.01
22
203
25
203
1.31
0.48
2.8
2.4
—
—
—
0
0
80
751
1.30
0.46
4.6
4.5
1.34
1.30
mmol/l
0.22
72
684
6
93
0.62
0.44
5.2
9.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
5.44
—
0
9
0
18
0.00
0.40
0.0
2.1
—
—
—
0
0
26
218
1.26
0.39
3.3
3.3
0.63
0.73
ug/l
0.40
17
132
41
366
1.20
0.35
4.1
4.4
26.54
36.33
ng/l
0.44
27
289
11
88
1.28
0.23
1.9
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
5.6
—
65.88
—
0
11
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
3.9
—
13.20
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
1.17
—
0
6
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
33
302
1.14
0.19
4.0
4.0
17.79
8.63
mg/mmol
0.36
12
195
29
268
1.11
0.14
4.3
4.9
0.00
0.03
estimate
0.74
13
93
10
86
1.18
0.11
4.0
7.9
1.12
1.29
mmol/l
—
10
86
7
65
1.08
0.08
6.3
7.7
25.17
24.68
mmol/l
—
7
65
8
94
0.84
0.07
2.9
2.0
216.13
372.97
nmol/l
—
8
86
45
465
0.94
0.07
3.6
2.8
—
—
—
0
0
12
112
1.08
0.03
1.4
1.4
—
—
—
0
0
5
54
0.92
0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
11.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
13.74
—
0
5
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
3.69
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
44.74
—
0
5
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PARAPSO_PLAQUE and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_PLAQUE | 0.861 [0.68, 1.09] | 0.211 |
| Birth year | 0.982 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 89 out of 367 males with L12_PARAPSO_PLAQUE died.
Mortality risk
Mortality risk for people of age
years, who have L12_PARAPSO_PLAQUE.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.148% |
| 5 | No data | 0.872% |
| 10 | No data | 2.253% |
| 15 | No data | 4.263% |
| 20 | No data | 7.145% |
Relationships between endpoints
↥Index endpoint: L12_PARAPSO_PLAQUE – Small plaque parapsoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data